DARE Dare Bioscience, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1401914 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2,570.3%
TTM net income YoY39.4%
TTM EPS YoY66.7%
Revenue 3-yr CAGR12.2%
Net income 3-yr CAGR—
Margins
Gross margin26.4%
Operating margin-746.1%
Net margin-749.8%
FCF margin-1,279.2%
EBITDA margin-592.2%
Returns
ROE-407.1%
ROA-40.0%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets89.4%
Debt / equity0.00x
Current ratio1.23x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.66x
Accruals ratio26.4%
Payout ratio—
Capex / revenue34.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $47,628 | $187,546 | $152,455 | $1.02M | $2,262 | -$21,172 | $25,427 | -$63,647 |
| Cost of revenue | $180,479 | $319,889 | $242,325 | $295,799 | $0 | $0 | $0 | — |
| Gross profit | -$132,851 | -$132,343 | -$89,870 | $727,877 | $2,262 | -$21,172 | $25,427 | — |
| R&D expense | $318,906 | $241,966 | $660,462 | $622,041 | $1.18M | $1.43M | $2.30M | $3.34M |
| SG&A expense | $2.64M | $2.59M | $2.25M | $1.58M | $2.50M | $2.38M | $2.31M | $2.00M |
| Operating income | -$3.09M | -$2.97M | -$3.00M | -$1.47M | -$3.67M | -$3.83M | -$4.58M | -$5.39M |
| Net income | -$3.16M | -$2.98M | -$3.00M | -$1.44M | -$3.56M | -$4.02M | -$4.38M | -$5.51M |
| EBITDA | -$2.58M | -$2.40M | -$2.44M | -$936,873 | -$3.19M | -$3.37M | -$4.41M | -$5.38M |
| EPS (basic) | -0.18 | -0.20 | -0.21 | — | -0.28 | -0.45 | -0.50 | — |
| EPS (diluted) | -0.18 | -0.20 | -0.21 | — | -0.28 | -0.45 | -0.50 | — |
| Weighted avg. shares (diluted) | 17.42M | 14.89M | 14.52M | — | 12.76M | 8.87M | 8.76M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $11.53M | $12.62M | $18.52M | $24.71M | $23.08M | $5.04M | $10.33M | $16.00M |
| Current assets | $16.92M | $16.69M | $21.66M | $27.06M | $25.00M | $6.60M | $11.82M | $18.45M |
| PP&E, net | $1.51M | $1.42M | $1.45M | $1.56M | $1.66M | $1.65M | $1.48M | $1.34M |
| Total assets | $22.10M | $22.37M | $27.83M | $32.47M | $30.75M | $12.98M | $18.62M | $22.10M |
| Current liabilities | $13.71M | $16.92M | $21.12M | $23.69M | $21.22M | $19.22M | $21.19M | $21.61M |
| Short-term debt | — | — | — | — | $10,542 | $187,966 | $91,907 | $4,054 |
| Total liabilities | $19.76M | $22.93M | $27.09M | $29.63M | $27.89M | $25.71M | $28.18M | $28.11M |
| Shareholders' equity | $2.34M | -$560,100 | $734,451 | $2.84M | $2.86M | -$12.73M | -$9.56M | -$6.01M |
| Shares outstanding | 19.67M | 15.17M | 14.56M | 14.50M | 13.93M | 9.03M | 8.85M | 8.70M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.85M | -$6.78M | -$5.52M | $1.58M | -$578,008 | -$5.42M | -$5.47M | $5.31M |
| Capital expenditure | $201,928 | $80,586 | $0 | $206,641 | $174,702 | -$153,396 | $157,331 | $562,849 |
| Free cash flow | -$7.05M | -$6.86M | -$5.52M | $1.37M | -$752,710 | -$5.26M | -$5.63M | $4.74M |
| Investing cash flow | -$201,928 | -$80,586 | $0 | -$206,641 | -$174,702 | $153,396 | -$157,331 | -$562,849 |
| Financing cash flow | $5.96M | $951,217 | -$715,470 | $424,129 | $18.65M | -$43,794 | $246,577 | -$132,012 |
| Depreciation & amortization | $511,013 | $572,143 | $554,643 | $534,395 | $481,906 | $454,165 | $175,642 | $6,368 |
| Stock-based compensation | $400,000 | $286,602 | $455,064 | $357,160 | $400,000 | $359,018 | $377,357 | $489,260 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.